Colitis induced by Lenvatinib in a patient with advanced hepatocellular carcinoma.
Colitis
Hepatocellular carcinoma
Lenvatinib
Multikinase inhibitor
Journal
Clinical journal of gastroenterology
ISSN: 1865-7265
Titre abrégé: Clin J Gastroenterol
Pays: Japan
ID NLM: 101477246
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
10
07
2020
accepted:
17
09
2020
pubmed:
8
10
2020
medline:
29
6
2021
entrez:
7
10
2020
Statut:
ppublish
Résumé
Lenvatinib is a standard molecular targeted agent for the first-line treatment of unresectable hepatocellular carcinoma. Here, we report a case of colitis induced by Lenvatinib treatment in a patient with hepatocellular carcinoma. A 78-year-old man previously treated with Lenvatinib for unresectable hepatocellular carcinoma was admitted to our hospital complaining of right lateral abdominal pain without diarrhea. Our endoscopic findings showed multiple ulcers and erosions on his ascending colon, and he was diagnosed with colitis induced by Lenvatinib treatment. After the discontinuation of Lenvatinib, his colitis improved, and he resumed Lenvatinib at a lower dose. Colitis is a rare adverse event of Lenvatinib, and this is the first detailed report of colitis induced by Lenvatinib with endoscopic findings.
Identifiants
pubmed: 33025343
doi: 10.1007/s12328-020-01249-7
pii: 10.1007/s12328-020-01249-7
doi:
Substances chimiques
Phenylurea Compounds
0
Quinolines
0
lenvatinib
EE083865G2
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
187-192Références
Matsui J, Yamamoto Y, Funahashi Y, et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008;122:664–71.
doi: 10.1002/ijc.23131
Matsui J, Funahashi Y, Uenaka T, et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res. 2008;14:5459–65.
doi: 10.1158/1078-0432.CCR-07-5270
Tohyama O, Matsui J, Kodama K, et al. Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res. 2014;2014:638747.
doi: 10.1155/2014/638747
Yamamoto Y, Matsui J, Matsushima T, et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell. 2014;6:18.
doi: 10.1186/2045-824X-6-18
Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372:621–30.
doi: 10.1056/NEJMoa1406470
Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163–73.
doi: 10.1016/S0140-6736(18)30207-1
Oda K, Matsunaga T, Sennari K, et al. Colitis associated with nintedanib therapy for idiopathic pulmonary fibrosis (IPF). Intern Med. 2017;56:1267–8.
doi: 10.2169/internalmedicine.56.8065
Cornelissen L, Claus F, Wolter P, et al. Incidence of bowel wall oedema on computed tomography exams and association with diarrhoea in renal cell carcinoma patients treated with sunitinib. Eur Radiol. 2015;25:375–9.
doi: 10.1007/s00330-014-3389-1
Suzuki N, Tajiri K, Futsukaichi Y, et al. Perforation of the small intestine after introduction of Lenvatinib in a patient with advanced hepatocellular carcinoma. Case Rep Gastroenterol. 2020;14:63–9.
doi: 10.1159/000505774
Kamba T, Tam BYY, Hashizume H, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol. 2006;290:H560–H576576.
doi: 10.1152/ajpheart.00133.2005
Terme M, Colussi O, Marcheteau E, et al. Modulation of immunity by antiangiogenic molecules in cancer. Clin Dev Immunol. 2012;2012:492920.
doi: 10.1155/2012/492920
Katoh M. FGFR inhibitors: effects on cancer cells, tumor microenvironment and whole-body homeostasis. Int J Mol Med. 2016;38:3–15.
doi: 10.3892/ijmm.2016.2620
Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicenter trial. Lancet Oncol. 2015;16:1473–82.
doi: 10.1016/S1470-2045(15)00290-9
Makker V, Taylor MH, Aghajanian C, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J Clin Oncol. 2020. https://doi.org/10.1200/JCO.19.02627 .
doi: 10.1200/JCO.19.02627
pubmed: 32167863
pmcid: 7479759